Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Pelthos Therapeutics's pretax income for the
three
months ended in Jun. 2026 was $-23.42 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $-78.94 Mil.
Pelthos Therapeutics's pretax margin was -150.08%.
During the past 6 years, Pelthos Therapeutics's highest Pretax Margin was -182.30%. The lowest was -330.50%. And the median was -316.21%.
During the past 6 years, Pelthos Therapeutics's highest Pretax Margin was -182.30%. The lowest was -330.50%. And the median was -316.21%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pelthos Therapeutics Pre-Tax Income Related Terms
Pelthos Therapeutics Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Pelthos Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTHS vs KLRS, FBIO, VRCA: Pre-Tax Income Comparison
For the Biotechnology subindustry, Pelthos Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pelthos Therapeutics Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pelthos Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Pelthos Therapeutics's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-78.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pelthos Therapeutics (PTHS) has a Pre-Tax Income of $-78.94 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Pelthos Therapeutics and its competitors.
Is Pelthos Therapeutics' Pre-Tax Income too high?
Pelthos Therapeutics' current Pre-Tax Income is $-78.94 Mil. Overall, Pelthos Therapeutics has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Pelthos Therapeutics' Pre-Tax Income compare to KLRS and FBIO?
Pelthos Therapeutics' Pre-Tax Income of $-78.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Pelthos Therapeutics and its competitors. Pelthos Therapeutics's current Pre-Tax Income is $-78.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pelthos Therapeutics stock overvalued right now?
Pelthos Therapeutics (PTHS) has a current Pre-Tax Income of $-78.94 Mil. The current Pre-Tax Income is $-78.94 Mil. Pelthos Therapeutics' overall GF Score™ is 4/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Pelthos Therapeutics (PTHS), the current Pre-Tax Income is $-78.94 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
4GF Score
Get the complete analysis for PTHS
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTHS has been successfully added to your 
